Benzinga | Apr 19, 2021 09:12AM EDT

LivaNova Says Has Randomized 300ty Patient In ANTHEM-HFrEF Pivotal Study

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study, which was approved by the U.S. Food and Drug Administration (FDA) under the Breakthrough Devices Program.